Physician

Faina Gurevich, M.D.

According to 2025 Medicare claims, Faina Gurevich, M.D. (NPI: 1457535031) practices nephrology in the Johnstown, PA market, with the plurality of this provider's patient population coming from Cambria, PA. This provider's primary affiliated billing organization is LAUREL KIDNEY SPECIALISTS,P.C. (NPI: 1942374277; TIN: 251887757) and primary practice location at 15901-1601. Gurevich is affiliated with the AdvantagePoint Health Alliance - Laurel Highlands, LLC (ACO ID: A4657), participating under the MSSP model.

Gurevich's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 371 traditional Medicare patients, billed 1,859 HCPCS/CPT codes, and received $111,722 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 3,276 prescription claims across 480 beneficiaries totaling $350,954 in drug costs, led by Jardiance (Empagliflozin). DME data shows 14 claims. Open Payments data shows 2 records totaling $54. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $95,821 to $111,722. Similarly, Part D prescription costs have moved from a higher plateau to a lower plateau, from $508,567 to $350,954. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	194	1,165	$95,821
2016	386	2,468	$246,611
2017	376	1,970	$216,549
2018	438	2,477	$266,546
2019	527	3,142	$296,602
2020	469	2,317	$229,960
2021	459	1,917	$213,770
2022	377	1,692	$152,133
2023	349	1,896	$122,937
2024	371	1,859	$111,722

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	286	3,108	$508,567
2016	314	3,276	$558,299
2017	330	3,289	$601,342
2018	358	3,021	$274,327
2019	389	2,765	$245,107
2020	390	2,732	$209,258
2021	380	2,713	$196,704
2022	395	3,093	$258,588
2023	391	3,256	$363,186
2024	480	3,276	$350,954

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	200	$69,883
2016	N/R	200	$107,929
2017	N/R	162	$90,077
2018	N/R	153	$101,176
2019	N/R	155	$103,927
2020	N/R	152	$101,639
2021	N/R	44	$3,033
2022	N/R	81	$2,277
2023	N/R	29	$398
2024	N/R	14	$263

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	96	118	$129
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	144	257	$63
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	136	500	$60
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	47	74	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	85	120	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	78	2,788	$55,075
Farxiga	Dapagliflozin Propanediol	47	2,455	$44,068
Velphoro	Sucroferric Oxyhydroxide	12	345	$40,229
Procrit	Epoetin Alfa	29	798	$33,291
Cinacalcet Hcl	Cinacalcet Hcl	58	3,280	$26,479

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$263

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$54	AKEBIA THERAPEUTICS INC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Faina Gurevich, M.D.?

Tedicare shows public-source Medicare data for Faina Gurevich, M.D. (NPI 1457535031), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Faina Gurevich, M.D. have ACO affiliation data?

Faina Gurevich, M.D. is shown with ACO affiliation data for AdvantagePoint Health Alliance - Laurel Highlands, LLC (MSSP, ACO ID A4657).

What billing organization is linked to Faina Gurevich, M.D.?

Faina Gurevich, M.D. is linked to LAUREL KIDNEY SPECIALISTS,P.C. (billing NPI 1942374277) in the available physician profile data.

Does Faina Gurevich, M.D. have Open Payments data?

Faina Gurevich, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.